Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSPRI: Proton SFRT vs Photon SBRT with Pembrolizumab in Oral Cavity Cancer
NCT07783581Phase 2Not yet recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2026
- Primary completion
- Apr 2030
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in oral cavity squamous cell carcinoma (OCSCC), sponsored by Mayo Clinic. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT07783581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783581.